Category: Cardiovascular protection

In summary, cAMP levels regulated by PDE4 and PDE2 may up-regulate the nitric oxide-cGMP pathway in endothelial cells. Conversely, in smooth muscle cells cGMP (related to nitric oxide) may down-regulate PDE3 and therefore potentiate the effect of PDE4 inhibition. Reciprocal interactions between cAMP and cGMP are favoured by nitric oxide in endothelial cells, as in vascular smooth muscle cells.  Taken together these results support the hypothesis that cGMP (related to nitric oxide production) enhances cAMP-mediated relaxation via the inhibition of PDE3. Glad you are finally going to spend less time and money shopping for the treatment you need? Our will be glad to give you that and a lot more when you become a customer, because health is very important to us.

CONCLUSIONS
…Read the rest of this article

In the presence of PDE3 inhibitor, the EC50 values of PDE4 inhibitors were two- to sixfold their IC50 values on purified vascular PDE4. The presence of functional endothelium decreased EC50 values of PDE4 inhibitors equivalent to their IC50 values on the enzyme . Therefore, PDE3 inhibition and the presence of functional endothelium both enabled the relaxing effect of PDE4 inhibition. This suggests that PDE3 inhibition by endogenous cGMP or by exogenous inhibitor is a prerequisite to the endothelium-dependent relaxing effect of PDE4 inhibitors.
…Read the rest of this article

Because rolipram acts specifically on PDE4, which hydrolyzes only cAMP, this L-arginine-dependent increase in cGMP level suggests that an increase in cAMP level may up-regulate the basal L-arginine-nitric oxide-cGMP pathway in endothelial cells.Vascular smooth muscle: Vascular smooth muscle cells contain PDE3 and PDE4 as major cAMP-hydrolyzing enzymes . Because the cGMP increase related to nitric oxide production may potentially inhibit PDE3, the respective roles of PDE3 and PDE4 were investigated on cyclic nucleotide levels and on relaxation of precontracted aorta with and without endothelium, in the presence or absence of nitric oxide donor. You are always welcome to visit the about canadian neighbor pharmacy for your drugs to be delivered right on time and just as promised. This is the best place to shop for the treatment you need at this point.
…Read the rest of this article

 As shown in Figure 2A, neither the PDE2 inhibitor nor the PDE4 inhibitor alone increased cAMP level, regardless of presence or absence of nitric oxide-cGMP pathway modulators. However, the combination of both inhibitors potently increased cAMP levels (eight- to 13-fold compared with drug vehicle). In the same samples, no significant effects of PDE2 and PDE4 inhibitors (alone or in combination) were observed on cGMP contents in control and L-NAME treated cells. Surprisingly, in the presence of the nitric oxide synthase substrate, cGMP content was increased significantly by the PDE4 inhibitor. Combination of PDE2 and PDE4 inhibitors resulted in a marked increase in cGMP level (to 153%, Figure 2B). None of these effects was observed when the nitric oxide synthase inhibitor was added with the nitric oxide synthase substrate. …Read the rest of this article

Reciprocal regulations between nitric oxide and cyclic nucleotides – role of cyclic nucleotide phosphodiesterases: By increasing tissue cGMP levels, nitric oxide may interfere with cyclic nucleotide metabolism and, therefore, participate in the regulation of vascular relaxation. Cyclic nucleotide PDE comprises seven families of isozymes that hydrolyze cyclic nucleotides . Among them, PDE2, PDE3 and PDE4 hydrolyze cAMP, but are differentially sensitive to cGMP. PDE2 is activated, whereas PDE3 is inhibited, by cGMP. …Read the rest of this article

Recently, in accordance with these observations, the appearance of EPR-detectable myoglobin-nitric oxide was found in S-nitrosoglutathione-pretreated rat hearts, after prolonged ischemia, but not in nonischemic hearts . Both LPS and S-nitrosoglutathione pretreatment are associated with cardioprotection against ischemia-reperfusion injury.Therefore, it might be suggested that stimulated nitric oxide production during a preischemic period may lead to the formation of heme (and perhaps nonheme-like in vascular tissue) nitrosyl iron complexes during a long lasting ischemia, and these complexes may play a beneficial role against the injury that occurs during reperfusion (Figure 1). …Read the rest of this article

cardiovascular protection (part 5)

It is known that nitric oxide may form nitrosyl iron heme complexes as well as iron nonheme complexes with thiol ligands both in vitro and in vivo. These can be detected by EPR spectroscopy . Low oxygen tension is favourable for the formation of such complexes . Therefore, one can suggest that increased nitric oxide level under ischemic conditions may increase the tissue content of nitro-syliron complexes.
…Read the rest of this article